BridgeBio Pharma (BBIO) Azione Prezzo
BridgeBio Pharma Prezzo
Il fatturato è cresciuto a un tasso composto del 52,1% annuo negli ultimi 6 anni, raggiungendo 502,08 Mio. USD. Il margine netto di BridgeBio Pharma si attesta al -145,3%, in aumento rispetto al -806,9% di alcuni anni fa. Gli analisti fissano un target di prezzo mediano di 106,50 USD, ovvero il 56,2% sopra il prezzo attuale. Su 29 analisti, 26 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
BridgeBio Pharma Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
BridgeBio Pharma Azione e analisi azionaria
Domande frequenti sull'azione BridgeBio Pharma
BridgeBio Pharma Inc is a biopharmaceutical company specializing in the development and commercialization of genetic medicines. The company aims to identify and advance therapies for diseases with clear genetic causes, leveraging its deep understanding of molecular pathways and human biology. BridgeBio Pharma Inc follows a diversified business model, which includes creating subsidiary companies focused on developing treatments for specific genetic diseases. These subsidiaries collaborate with academic institutions and industry partners to expedite the development of innovative therapies. By focusing on genetically driven diseases and utilizing a collaborative approach, BridgeBio Pharma Inc strives to bring transformative treatments to patients in need.
BridgeBio Pharma Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of BridgeBio Pharma Inc in the market include companies such as Amgen Inc, Gilead Sciences Inc, Biogen Inc, and Vertex Pharmaceuticals Incorporated.
BridgeBio Pharma Inc is a leading pharmaceutical company specializing in the development and commercialization of targeted therapies for genetic diseases and cancers. Founded in 2015, BridgeBio Pharma Inc has rapidly grown into a prominent player in the biotechnology industry. The company's mission is to identify and advance transformative medicines that address the unmet needs of patients with genetically driven conditions. With its innovative pipeline of candidates, BridgeBio Pharma Inc aims to make a meaningful impact on patients' lives. By leveraging its deep expertise in genetics and drug development, the company is poised to revolutionize the treatment landscape for various rare diseases and oncology indications.
BridgeBio Pharma Inc has achieved several significant milestones since its inception. The company has successfully developed a diverse pipeline of investigative compounds across multiple therapeutic areas, including genetically defined diseases and cancers. BridgeBio Pharma has also formed strategic partnerships with leading pharmaceutical companies to accelerate the development and commercialization of its promising candidates. Additionally, the company has received regulatory approvals for several of its therapeutics and has successfully advanced them into clinical trials. These milestones highlight BridgeBio Pharma's commitment to addressing unmet medical needs and advancing innovative therapies for patients around the world.
BridgeBio Pharma Inc is primarily present in the United States.
BridgeBio Pharma Inc represents a commitment to innovative solutions and transformative therapies. Guided by a strong corporate philosophy, the company focuses on addressing unmet medical needs and improving patient outcomes. BridgeBio Pharma Inc pioneers in developing targeted medicines for genetic diseases and cancers. With their dedication to scientific excellence, they identify potential drug candidates and accelerate their development through collaborations and partnerships. By leveraging cutting-edge research and technological advancements, BridgeBio Pharma Inc aims to positively impact the lives of patients and families affected by rare genetic disorders.
Gli analisti fissano attualmente un prezzo obiettivo medio di 107,92 USD per l’azione BridgeBio Pharma (mediana: 106,50 USD), pari a +58,3 % rispetto all’ultimo prezzo. Il consenso si basa su 29 giudizi di analisti.
29 analisti valutano attualmente l’azione BridgeBio Pharma: 26 raccomandano l’acquisto, 3 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per BridgeBio Pharma ricavi pari a 1,03 miliardi USD e un utile per azione di -2,71 USD.
Convertita al tasso di cambio attuale, l’azione BridgeBio Pharma quota 60,77 EUR (68,17 USD).
L’azione BridgeBio Pharma (BBIO) è quotata su 3 borse, tra cui: NASDAQ (BBIO), München (2CL.MU), Düsseldorf (2CL.DU).
BridgeBio Pharma Inc. is a biotechnology company focused on developing drugs for rare diseases. The company was founded in 2015 and is based in Palo Alto, California. Its business model is based on identifying and developing therapy approaches for rare diseases. BridgeBio works closely with researchers, academics, and other biotech companies to develop innovative therapies. It has a strong pipeline of drug candidates in preclinical and clinical studies. Flagship products include Infigratinib for FGFR2-gene defined cholangiocarcinoma and BBP-265 for ACADVL deficiency. BridgeBio has partnerships with major pharmaceutical companies such as Pfizer and Roche. It focuses on rare diseases, taking advantage of the limited treatment options and strong need in these patient populations. The company is funded through investments from venture capital firms and public institutions. It had a successful IPO in June 2019, raising nearly $350 million for pipeline development and financing teams working on new therapies. Overall, BridgeBio's business model is centered on identifying and developing therapies for rare diseases, with a strong pipeline and partnerships in place.
Il attesa fatturato di BridgeBio Pharma ammonta a 1,03 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di BridgeBio Pharma ammonta a -534,40 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di BridgeBio Pharma è attualmente -25,16. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione BridgeBio Pharma.
Il rapporto prezzo/fatturato (P/S) di BridgeBio Pharma è attualmente 13,08. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione BridgeBio Pharma.
Il Quality Score AlleAktien per BridgeBio Pharma è 3/10.
L'ISIN di BridgeBio Pharma è US10806X1028. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di BridgeBio Pharma è A2PLX7. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di BridgeBio Pharma è BBIO. Con questo simbolo di borsa vengono negoziate le azioni BridgeBio Pharma in borsa.
Azione BridgeBio Pharma
Gruppo di pari di BridgeBio Pharma
BridgeBio Pharma Ticker
BridgeBio Pharma FIGI
Altre metriche e analisi di BridgeBio Pharma in Deep Dive.
La nostra analisi azionaria dell'azione BridgeBio Pharma include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di BridgeBio Pharma. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: